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Background and Aims. Human embryonic stem cell- (hESC-) derived cardiomyocytes are one of the useful screening platforms
of potential cardiocytoprotective molecules. However, little is known about the behavior of these cardiomyocytes in simulated
ischemia/reperfusion conditions. In this study, we have tested the cytoprotective effect of an NO donor and the brain type
natriuretic peptide (BNP) in a screening platform based first on differentiated embryonic bodies (EBs, 6 + 4 days) and then
on more differentiated cardiomyocytes (6 + 24 days), both derived from hESCs. Methods. Both types of hESC-derived cells
were exposed to 150min simulated ischemia, followed by 120min reperfusion. Cell viability was assessed by propidium iodide
staining. The following treatments were applied during simulated ischemia in differentiated EBs: the NO-donor S-nitroso-N-
acetylpenicillamine (SNAP) (10−7, 10−6, and 10−5M), BNP (10−9, 10−8, and 10−7M), and the nonspecific NO synthase inhibitor N𝜔-
nitro-L-arginine (L-NNA, 10−5M). Results. SNAP (10−6, 10−5M) significantly attenuated cell death in differentiated EBs. However,
simulated ischemia/reperfusion-induced cell death was not affected by BNP or by L-NNA. In separate experiments, SNAP (10−6M)
also protected hESC-derived cardiomyocytes. Conclusions. We conclude that SNAP, but not BNP, protects differentiated EBs or
cardiomyocytes derived from hESCs against simulated ischemia/reperfusion injury.The present screening platform is a useful tool
for discovery of cardiocytoprotective molecules and their cellular mechanisms.
1. Introduction
Ischemic heart disease is the leading cause of mortality in
the Western world; therefore, the development of cardio-
protective therapies is currently a main focus of research.
In vitro cardiac myocyte-based drug-screening platforms are
widely used, especially at the early stage of the develop-
ment of cardioprotective agents. However, these assays are
based on cardiomyoblast cell lines or primary neonatal and
adult cardiac myocytes [1] and thus have major limitations,
including a low proliferation capacity, uncontrolled stress
during cell isolation, low throughput, and poor predictability
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of the assays towards in vivo efficacy [2]. Moreover, the
relationship between drug responses from animal-derived
primary cardiomyocytes and their human counterparts may
be significantly different [3]. Human embryonic stem cells
(hESCs) are capable of differentiating towards cardiac lin-
eages [4]; therefore, hESCs provide a promising source of
cardiomyocytes for in vitro drug screening [5, 6]. In addition,
hESCs may also provide new tools for regenerative therapies
[7–9].
Despite the encouraging results and the enormous poten-
tial of the hESC-derived cardiomyocytes, several complica-
tions need to be overcome regarding their therapeutic uti-
lization, such as ethical problems, tumor formation, and
immunoreactivity. Moreover, it has been demonstrated that
the survival of implanted cells is enormously reduced after
transplantation [10–12], with these cells undergoing a signif-
icant cell death within the first 24 hours [13]. A plausible
reason for this effect is the unfavorable microenvironment
the grafted cells face when injected into the ischemic host
myocardium. Characterization of these cells in an ischemia/
reperfusion test system thus would be important, since little
is known about the ischemic tolerance of hESC-derived
cardiomyocytes.
We have previously shown that the nitric oxide donor
S-nitroso-n-acetylpenicillamine (SNAP) and the particulate
guanylate cyclase activator B-type natriuretic peptide (BNP)
exert a cytoprotective effect against simulated ischemia/
reperfusion (SI/R) injury in primary neonatal rat cardiomy-
ocytes [14]. More recently, the cytoprotective effect of SNAP
has been shown in mouse embryonic stem cell- (mESC-)
derived cardiomyocytes subjected to SI/R treatment [15].
This protection occurs via the activation of protein kinase G
(PKG) and stimulation of its downstream signal transduction
pathway, which leads to increased cell viability against SI/R
injury [14–17]. However, this cytoprotective effect of SNAP
and BNP against SI/R injury has not been explored as yet in
human cardiomyocytes derived from hESCs.
Therefore, the aim of this present study was to test
whether the nitric oxide donor SNAP and the particulate
guanylate cyclase activator BNP can protect hESC-derived
cardiomyocytes against SI/R injury.
2. Methods
2.1. Human Embryonic Stem Cell Culture. The CAG
promoter driven eGFP expressing human HUES9 stem
cell culture (Ethic license: Hungarian Committee of
Human Reproduction; 31681-1/2004-1016EHR12534-0/2009-
1016EHR; ES2HEART consortium) [18, 19] was dispersed by
0.5mg/mL collagenase type IV (Gibco, Invitrogen; Carlsbad,
CA, USA) dissolved in KnockOut Dulbecco’s Modified
Eagle Medium (Gibco). Subsequently, cells were maintained
in cell suspension culture for 6 days in KnockOut Dulbecco’s
Modified Eagle Medium (Gibco), supplemented with 20%
embryonic stem cell-qualified fetal bovine serum (Gibco),
1% nonessential amino acids, 1% L-glutamine (Gibco),
and 0.2% beta-mercaptoethanol (Gibco). To allow clump
formation, cell attachment was hampered by using polyhema
(5mg/mL, Sigma; St. Louis, MO, USA) coated surface. After
6 days, the formation of small clumps was observed which
are designated as embryonic bodies (EBs).
2.2. Differentiation of EBs and Cardiomyocytes Derived from
Human Embryonic Stem Cells. Six-day-old EBs were seeded
onto gelatin-coated coverslips in 24-well plates. 5–10 EBswere
plated into each well. Differentiation of EBs was supported by
differentiating media containing Dulbecco’s Modified Eagle
Medium (Sigma) supplemented with 15% fetal bovine serum
(Gibco). EBs were kept under normal conditions (at 37∘C, in
95% air and 5% CO
2
gas mixture) for 4 days prior to SI/R
experiments.
In separate experiments, hESC-derived EBs were main-
tained in differentiating medium for 24 days. At this
stage of their differentiation, spontaneous contractions were
observed as the sign of the formation of mature cardiac
tissues, and these areas were designated as cardiomyocyte-
rich region of EBs.
2.3. Real-Time PCR Analysis of Differentiated EBs. Cardiac-
oriented differentiation of the cells was documented in
differentiated EBs by real-time quantitative PCR analysis.
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen; Carlsbad, CA, USA). Subsequently, cDNA sam-
ples were prepared from 1 𝜇g total RNA using the Promega
Reverse Transcription SystemKit (PromegaCorp.; Fitchburg,
WI, USA). All these steps were performed according to
the manufacturer’s instructions. For real-time quantitative
PCR, the following predeveloped TaqMan assays were pur-
chased from Applied Biosystems (Thermo Fisher Scientific;
Waltham,MA, USA): octamer-binding transcription factor 4
(OCT4) and the divergent homeodomain proteinNANOGas
undifferentiated stem cell markers [20–22], BRACHYURY as
mesoderm marker [23], the homeobox protein NKX2.5 and
the zinc finger transcription factor GATA4 as early markers
of cardiac differentiation [24, 25], and activated leukocyte
cell adhesion molecule (CD166, ALCAM) as a marker of
cardiomyocytes [26]. P0 ribosomal protein was used as
endogenous control for quantification. Real-time PCR anal-
yses were carried out using the StepOne Real-Time PCR
System (Applied Biosystems), according to the manufac-
turer’s instructions. The fold changes of mRNA in experi-
mental and control cells were determined using the 2−ΔΔCt
method. Relative mRNA levels were presented as mean ±
SEM of 3 independent experiments.
2.4. Immunofluorescence. In order to test the specificity of
CAG-driven eGFP expression during cardiac differentiation,
immunostaining of cardiac troponin I (cTnI) was performed
in 6 + 24-day-old adherent EBs. Samples were fixed with
4% paraformaldehyde in Dulbecco’s modified phosphate
buffered saline (D-PBS, Sigma) for 15min at room tem-
perature, followed by three washing steps with D-PBS. To
block nonspecific antibody binding, samples were incubated
in D-PBS containing 2mg/mL bovine serum albumin, 1%
fish gelatin, 5% goat serum, and 0.1% Triton-X 100 for 1 h
at room temperature. The samples were then incubated with
primary antibodies (monoclonal mouse anti-cTnI, Sigma)
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Figure 1: Experimental design of simulated ischemia (SI) and reperfusion (R). hESC-derived EBs (6 + 4 days of differentiation) and
differentiated cardiomyocytes (6 + 24 days of differentiation) were exposed to 150min SI, followed by 120min R. Cell viability was assessed
by propidium iodide staining. The following treatments were applied during SI in differentiated EBs (6 + 4 days of differentiation): the NO-
donor S-nitroso-N-acetylpenicillamine (SNAP) (10−7, 10−6, and 10−5M), BNP (10−9, 10−8, and 10−7M), and the nonspecific nitric oxide (NO)
synthase inhibitor N𝜔-nitro-L-arginine (L-NNA, 10−5M). In case of the hESC-derived cardiomyocytes (6 + 24 days of differentiation), 10−6M
SNAP was applied during SI. Viability data were normalized to the cardiac specific CAG-driven eGFP fluorescence.
at the dilution of 1 : 500 for 1 h at room temperature. After
washing with D-PBS, the cells were incubated with sec-
ondary antibodies (Alexa Fluor 568-conjugated goat anti-
mouse antibody, Invitrogen) for 1 h at room temperature.
Secondary antibodies were diluted in the blocking solution
at 1 : 250. 4󸀠,6-Diamidino-2-phenylindole⋅2HCl (DAPI, Invit-
rogen) was used for nuclear staining (10 𝜇M, for 10min in
D-PBS). The stained samples were examined by an Olympus
fluorescence microscope.
2.5. Experimental Groups. For cell viability experiments,
hESC-derived cells were tested under normoxic condition
or were subjected to SI (Figure 1). In normoxic conditions,
the differentiating medium was replaced with a normoxic
solution (inmM:NaCl 125, KCl 5.4, NaH
2
PO
4
1.2, MgCl
2
0.5,
HEPES 20, glucose 15, taurine 5, CaCl
2
1, creatine 2.5, BSA
0.1%, pH 7.4, and 310mOsm/L) and cells were incubated in
a normoxic incubator at 37∘C for 2.5 h. Regarding ischemic
conditions, the cells were subjected to SI by incubating them
in hypoxic solution (in mM: NaCl 119, KCl 5.4, MgSO
4
1.3,
NaH
2
PO
4
1.2, HEPES 5, MgCl
2
0.5, CaCl
2
0.9, Na-lactate
20, BSA 0.1%, 310mOsm/L, and pH = 6.4) and exposed
to a constant flow of a mixture of 95% N
2
and 5% CO
2
for 2.5 hours at 37∘C. Cells were subjected to the following
treatments during SI: (1) untreated control; (2) SNAP (10−7,
10−6, and 10−5M) (Sigma); (3) brain type natriuretic peptide-
32 (BNP, 10−9, 10−8, and 10−7M) (American Peptides); (4)
NOS inhibitor N-nitro-L-arginine (L-NNA, 10−5M) (Sigma).
Concentrations of the compounds were selected according to
our previous data [14, 15].
At the second set of experiments, cardiomyocytes derived
from hESCs were subjected to the following treatments
during SI: (1) untreated control; (2) SNAP (10−6M).
Either normoxic or SI treatments were followed by 2 h
reperfusion, when the previously applied solutions were
replaced with differentiating medium, and the cells were
maintained in a normoxic incubator, gassed with 95% air and
5% CO
2
at 37∘C.
2.6. Cell Viability Measurements. At the first set of experi-
ments with differentiated EBs derived from hESCs, after sim-
ulated reperfusion, cell viability was assessed by propidium
iodide (PI) assay as described previously [15]. Briefly, the
growthmediumwas removed, and the cells were washedwith
PBS twice and incubated with PI (50𝜇M, Sigma) for 7 min-
utes. Each experiment included a digitonin (10−4M, Sigma)
treated positive control. Then, PI solution was replaced
with fresh PBS and fluorescence intensity of each well was
detected by a fluorescent plate reader using 544 ex/610 em
filters (FluoStar Optima, BMG Labtech, Thermo Fisher Sci-
entific). PI intensity reflecting cell death was evaluated in
the cardiomyocyte-rich region. Since the elevation of eGFP
expression is associated with cardiac-oriented differentia-
tion of this hESCs model, the evaluation of cardiomyocyte
committed regions was performed manually on each plate
by detecting eGFP expression driven by the CAG promoter
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Figure 2: Real-time PCR analysis of differentiated EBs (6 + 4 days of differentiation). OCT4 and NANOG pluripotency markers were
downregulated (a), whereas mesodermal (BRACHYURY) and early and later cardiac markers (NKX2.5, GATA4, and ALCAM) were
upregulated (b) as compared to the undifferentiated human HUES9 embryonic stem cell line control. Data are expressed as mean ± SEM;
∗∗
𝑝 < 0.01, and ∗∗∗𝑝 < 0.001, differentiated EBs versus undifferentiated control; Student t-test, 𝑛 = 2.
(Supplemental Figure 1, in Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2016/4298945). The
cytoprotective effect of different compounds was compared
to simulated ischemic control groups, where cell death was
designated as 100 percent.
At the second set of experiments, cardiomyocytes derived
from hESCs underwent SI/R procedure similar to other
groups. Cell viability was assessed by the above-described
method.
2.7. Statistical Analysis. Results are expressed as mean ±
SEM. Unpaired t-test and one-way analysis of variance
(ANOVA) followed by Fisher’s least significant difference
(LSD) post hoc tests were used to determine differences in
mean values between the experimental groups. Differences
were considered significant at 𝑝 < 0.05.
3. Results
3.1. Cardiac Differentiation of EBs. Real-time quantitative
PCR analysis confirmed the cardiac-oriented development
of cells in differentiated EBs. Both OCT4 and NANOG
pluripotency markers were downregulated in the differenti-
ated EBs as compared to the undifferentiated human HUES9
embryonic stem cell line control (Figure 2). Additionally, the
expression of mesodermal (BRACHYURY) and early cardiac
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Table 1: Cell death of both differentiated EBs (6 + 4 days of
differentiation) and cardiomyocytes derived from hESCs (6 + 24
days of differentiation) exposed to normoxia or SI: representative
results obtained from one plate. Data are expressed as mean ± SEM;
𝑝 < 0.05 normoxia versus SI; unpaired 𝑡-test, 𝑛 = 5-6 in both groups.
(a) The effect of SI/R on cell death of differentiated EBs derived from hESCs
(6 + 4 days of differentiation)
Group Mean RFU ± SEM 𝑝 value
Normoxia 1141 ± 69.83 𝑝 = 0.0019
SI 3624 ± 516.2 (unpaired 𝑡-test)
(b) The effect of SI/R on cell death of hESC-derived cardiomyocytes (6 + 24
days of differentiation)
Group Mean RFU ± SEM 𝑝 value
Normoxia 65817 ± 10272 𝑝 = 0.0027
SI 137045 ± 17555 (unpaired 𝑡-test)
cTnI
immunostaining
eGFPDAPI
Merge
Figure 3: Colocalization of cTnI and enhanced CAG-driven eGFP
signals in cardiomyocytes derived from hESCs (6 + 24 days of
differentiation). Scale bar: 200 𝜇m.
markers (NKX2.5 and GATA4) were elevated at this stage
of differentiation. Moreover, the cardiac specific ALCAM
expression was also upregulated as compared to the control.
The specificity of CAG-driven eGFP expression dur-
ing cardiac differentiation was also documented. In later
stage EBs (6 + 24 days), an enhanced eGFP expression
was observed in cTnI positive cardiomyocytes derived from
hESCs, as confirmed by the colocalization of both signals
obtained by immunostaining of cTnI (Figure 3).
3.2. Cell Viability after SI/R. The cytoprotective effect of the
NO-donor SNAP that activates soluble guanylate cyclase
(sGC) was tested in the model of simulated ischemia (SI).
Reperfusion-induced cell death was monitored in differen-
tiated EBs as well as in cardiomyocytes derived from hESCs.
We found that SI followed by reperfusion caused significantly
higher cell death in differentiated EBs or cardiomyocytes than
in time-matched controls kept under normoxic conditions
(Table 1).
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Figure 4: Effect of SNAP on cell viability of differentiated EBs
derived from hESCs (6 + 4 days of differentiation). SNAP was
applied during SI. Data are expressed as mean ± SEM; ∗𝑝 < 0.05
SNAP treated versus SI control; ∗∗𝑝 < 0.01 SNAP treated versus
SI control; one-way ANOVA followed by Fischer LSD post hoc test,
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Figure 5: Effect of L-NNA on cell viability of differentiated EBs
derived from hESCs (6 + 4 days of differentiation). L-NNA was
applied during SI. Data are expressed as mean ± SEM; unpaired t-
test, 𝑛 = 4 in each group.
In differentiated EBs, cell death was significantly
decreased by SNAP in a concentration-dependent manner
when applied during the SI period (Figure 4).
The endogenous NO production was abolished by the
administration of the nonselective NOS inhibitor L-NNA at
10−5M concentration. The presence of L-NNA alone did not
influence cell death after SI (Figure 5). BNP, an activator of
particulate guanylate cyclase tested at 10−9, 10−8, and 10−7M
concentrations, did not influence cell death significantly
(Figure 6).
In order to confirm the cytoprotective effect of SNAP, it
was administered to hESC-derived cardiomyocytes. SNAP,
as compared to vehicle, attenuated cell death in the hESC-
derived cardiomyocytes at 10−6M concentration (Figure 7).
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Figure 6: Effect of BNP on cell viability of differentiated EBs derived
from hESCs (6 + 4 days of differentiation). BNP was applied during
SI. Data are expressed as mean ± SEM, 𝑛 = 8 in each group.
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Figure 7: Effect of SNAP on cell viability of hESC-derived car-
diomyocytes (6 + 24 days of differentiation). SNAP was applied
during SI. Data are expressed as mean ± SEM; ∗𝑝 < 0.05 SNAP
treated versus SI control; one-way ANOVA followed by Fischer LSD
post hoc test, 𝑛 = 8 in each group.
4. Discussion
Here, we show for the first time that the NO-donor SNAP
is able to provide cardiocytoprotective effect against SI/R-
induced cell death in a model of differentiated human
EBs as well as in contracting cardiomyocytes derived from
hESCs. Moreover, this study is the first demonstration of a
hESC-based drug-screening platform that is able to identify
cardioprotective compounds against SI/R injury.
Currently used primary cardiomyocyte-based or car-
diomyoblast cell line-based drug-screening platforms have
many limitations for their utilization. The disadvantages of
these assays strongly limit their applicability in preclinical
research. Primary neonatal cardiomyocytes are widely used
to test cardioprotective drugs; however, results may vary
due to culture variability introduced by the isolation proce-
dure or the limited proliferation [27]. Adult cardiomyocytes
are suitable to study individual cells, and particularly the
pharmacological properties of different ion channels can
be examined using this model. However, such cells require
special conditions during culturing, especially laminin coated
surface, which is indispensable for proper attachment and cell
survival [2]. Cell lines are preferable test systems for drug
screening, however presenting several limitations. The H9c2
cardiomyoblast line shows different phenotype even from
neonatal and adult cardiac myocytes, and additionally spon-
taneous electric activity and sarcomeric structure cannot be
observed in them [28]. Since the translational value of hESC-
based platforms for representing human conditions may be
substantially higher than the abovementioned cell culture
models, here we validated a hESC-derived cardiomyocyte-
based drug-screening platform to test cardioprotective agents
by using the well-known cardiocytoprotective NO-donor
SNAP [14, 15, 29–32].
In our experiments, we found that the NO-donor SNAP
increased the viability of differentiated EBs derived from
hESCs, subjected to SI/R. This protective effect was dose-
dependent, showing the same dose response characteristics
as found in neonatal rat cardiomyocytes [14] exposed to SI/R.
Our research had shown that NO exerts direct cardiocy-
toprotection via cGMP-PKG signaling pathway. Moreover,
another study on normoxic, neonatal rat cardiac myocyte
showed that SNAP caused significant necrosis at 1mM
concentration (no significant changes at 10 and 100 𝜇M), but
a bell-shaped effect on apoptosis was observed, that is, sig-
nificant increase at 100 𝜇M and no effect at 10 𝜇M and 1mM
[33].
Similar results were presented by our group on mouse
embryonic stem cell-derived cardiomyocytes, where NO had
concentration-dependent direct cytoprotective action and
soluble guanylate cyclase, PKG, and KATP channels play a
role in the downstream pathway of SNAP-induced cytopro-
tection [15]. Hsieh et al. showed recently that short pretreat-
ment with NO donor (NaNO
2
) combined with hypoxia pro-
tects neonatal cardiacmyocyte but not cardiac fibroblast from
hypoxic injury, and apoptosis decreased in humanES-derived
cardiac myocytes [34]. These results further suggest that NO
donors may protect stem cells implanted into ischemic areas
of the myocardium. Additionally, it has been shown that NO
is able to facilitate ESC differentiation and cardiomyogenesis
[35]. To investigate if endogenous NO affects ischemic toler-
ance of differentiated EBs derived from hESCs, a nonspecific
NOS inhibitor, L-NNA, was given during SI. L-NNA did
not affect cell viability after SI/R injury of differentiated EBs,
indicating that ischemic tolerance of these cells is not altered
by endogenous NO. However, local NO concentration largely
depends on the ratio of NO and local superoxide production
(see, for reviews, Ferdinandy and Schulz, 2003; Andreadou
et al., 2015) [36, 37]. Bioavailability of NO also depends on
NO synthase (NOS) expression, and previously it was shown
that NOS expression has a developmental stage-dependent
expression pattern in rat mouse embryos. Mouse EBs treated
with NOS inhibitor were prone to less differentiate after
embryonic age D-13. Here, we have shown, in human ES-
derived cardiacmyocytes, that NO has a direct cytoprotective
effect in early and more differentiated stage.
Intracellular biosynthesis of cGMP can be catalyzed by
both soluble (sGC) and particulate (pGC) guanylate cyclase.
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The activation of the same intracellular signaling pathway
was achieved by administration of BNP (activator of pGC)
which is an effective cardioprotective peptide. We have pre-
viously shown that exogenously administered BNP reduced
cell death after SI/R injury in neonatal rat cardiomyocyte
cultures [14] and reduced infarct size at nM concentration
range in rat hearts [38]. In agreement with our previous
finding in a mouse ESC-derived cardiomyocyte model [15],
the exogenously administered BNPwas not protective against
SI/R-induced cell death in differentiated EBs. The lack of
protection may be attributed to the low expression of the
NPR-A receptor (specific for BNP) during hESC differenti-
ation [39]. In another study, BNP significantly increased the
number of apoptotic neonatal cardiac myocytes subjected to
mild hypoxic stimulus (3%O
2
) in a concentration-dependent
manner (0.01; 0.1; 1 𝜇mol/L); however, it had no significant
effect on the number of necrotic cells [40].
hESC differentiation with suspension EB method results
in around 30% cardiac myocyte population [41]; however,
the efficacy of cardiac differentiation may vary depending
on stem cell line or experimental circumstances [7, 8, 42–
44]. Here, in our study, we were able to selectively investigate
cardiac myocyte population in the embryonic bodies by
using eGFP overexpression, which enhances the specificity of
screening platform.
In summary, here, we demonstrate for the first time that
SNAP, but not BNP, protects differentiated human EBs or
cardiomyocytes against SI/R injury. Our findings also suggest
that hESC-derived differentiated EBs containing early cardiac
committed cells may serve as a screening platform for the
discovery of cardiocytoprotectivemolecules; additionally, the
present platform is suitable for testing the cardiac myocyte
population of the EBs.
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